DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

NCT02633111 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

501

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma
Aggressive

Interventions

OTHER: collected at pre-treatment tumor biopsy
OTHER: Peripheral blood tests
DEVICE: PET/CT

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]